(Q81916869)
Statements
Phase II multicenter study of oblimersen sodium, a Bcl-2 antisense oligonucleotide, in combination with rituximab in patients with recurrent B-cell non-Hodgkin lymphoma (English)
Barbara Pro
Brian Leber
Jorge Romaguera
Fredrick Hagemeister
Alma Rodriguez
Peter McLaughlin
Felipe Samaniego
James Zwiebel
Adriana Lopez
Larry Kwak
1 September 2008